Treatment of cryptococcosis in the setting of HIV coinfection

References

• Mirza SA, Phelan M, Rimland D et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin. Infect. Dis.36, 789–794 (2003).
   PubMed Web of Science ®Google Scholar
• Hajjeh RA, Conn LA, Stephens DS et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J. Infect. Dis.179, 449–454 (1999).
   PubMed Web of Science ®Google Scholar
• Chen S, Sorrell T, Nimmo G et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis.31, 499–508 (2000).
   PubMed Web of Science ®Google Scholar
• Brandt ME, Hutwagner LC, Klug LA et al. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J. Clin. Microbiol.34, 912–917 (1996).
   PubMed Web of Science ®Google Scholar
• Hoang LM, Maguire JA, Doyle P, Fyfe M, Roscoe DL. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997–2002): epidemiology, microbiology and histopathology. J. Med. Microbiol.53, 935–940 (2004).
   PubMed Web of Science ®Google Scholar
• Tintelnot K, Lemmer K, Losert H, Schär G, Polak A. Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates. Mycoses47, 455–464 (2004).
   PubMed Web of Science ®Google Scholar
• Lizarazo J, Linares M, de Bedout C, Restrepo A, Agudelo CI, Castañeda E. Results of nine years of the clinical and epidemiological survey on cryptococcosis in Colombia, 1997–2005. Biomedica27, 94–109 (2007).
   PubMed Web of Science ®Google Scholar
• Poonwan N, Mikami Y, Poosuwan S et al. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents. Eur. J. Epidemiol.13, 335–340 (1997).
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections: a systematic review. Infection35, 51–58 (2007).
   PubMed Web of Science ®Google Scholar
• Lortholary O, Poizat G, Zeller V et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS20, 2183–2191 (2006).
   PubMed Web of Science ®Google Scholar
• Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis.43, 1069–1073 (2006).
   PubMed Web of Science ®Google Scholar
• Morgan J, McCarthy KM, Gould S et al.Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002–2004. Clin. Infect. Dis.43, 1077–1080 (2006).
   PubMed Web of Science ®Google Scholar
• Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr. HIV Res.5, 355–360 (2007).
   PubMed Web of Science ®Google Scholar
• Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; the French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med.4, e21 (2007).
   PubMed Web of Science ®Google Scholar
• Witt MD, Lewis RJ, Larsen RA et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin. Infect. Dis.22, 322–328 (1996).
   PubMed Web of Science ®Google Scholar
• Fan-Havard P, Yamaguchi E, Smith SM, Eng RH. Diastolic hypertension in AIDS patients with cryptococcal meningitis. Am. J. Med.93, 347–348 (1992).
   PubMed Web of Science ®Google Scholar
• Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect. Dis. Clin. North Am.20, 507–544 (2006).
   PubMed Web of Science ®Google Scholar
• Powderly WG. Current approach to the acute management of cryptococcal infections. J. Infect.41, 18–22 (2000).
   PubMed Web of Science ®Google Scholar
• Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet363, 1764–1767 (2004).
   PubMed Web of Science ®Google Scholar
• Micol R, Lortholary O, Sar B et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J. Acquir. Immune Defic. Syndr.45, 555–559 (2007).
   PubMed Web of Science ®Google Scholar
• Liechty CA, Solberg P, Were W et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop. Med. Int. Health12, 929–935 (2007).
   PubMed Web of Science ®Google Scholar
• Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis.30, 710–718 (2000).
   PubMed Web of Science ®Google Scholar
• van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med.337, 15–21 (1997).
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Powderly WG. Treatment of acute cryptococcal disease. Expert Opin. Pharmacother.2, 1259–1268 (2001).
   PubMedGoogle Scholar
• Hiemenz, JR, Walsh, TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis.22, S133 (1996).
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis.27, 603 (1998).
   PubMed Web of Science ®Google Scholar
• Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis.22, 315–321 (1996).
   PubMed Web of Science ®Google Scholar
• Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS11, 1463–1471 (1997).
   PubMed Web of Science ®Google Scholar
• Menichetti F, Fiorio M, Tosti A et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis.22, 838–840 (1996).
   PubMed Web of Science ®Google Scholar
• Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect. Dis.6, 118 (2006).
   PubMed Web of Science ®Google Scholar
• Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann. Intern. Med.113, 183–187 (1990).
   PubMed Web of Science ®Google Scholar
• Larsen RA, Bozzette SA, Jones BE et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis.19, 741–745 (1994).
   PubMed Web of Science ®Google Scholar
• Mayanja-Kizza H, Oishi K, Mitarai S et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis.26, 1362–1366 (1998).
   PubMed Web of Science ®Google Scholar
• Sobel JD. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Clin. Infect. Dis.39, S224–S227 (2004).
   PubMed Web of Science ®Google Scholar
• Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother.39, 598–601 (1995).
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis.36, 1221–1228 (2003).
   PubMed Web of Science ®Google Scholar
• de Gans J, Portegies P, Tiessens G et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS6, 185–190 (1992).
   PubMed Web of Science ®Google Scholar
• Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J. Med. Assoc. Thai.86, 293–298 (2003).
   PubMedGoogle Scholar
• Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med.149, 2301–2308 (1989).
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Larsen RA, Chiu J et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N. Engl. J. Med.324, 580–584 (1991).
   PubMed Web of Science ®Google Scholar
• Powderly WG, Saag MS, Cloud GA et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N. Engl. J. Med.326, 793–798 (1992).
   PubMed Web of Science ®Google Scholar
• Saag MS, Cloud GA, Graybill JR et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis.28, 291–296 (1999).
   PubMed Web of Science ®Google Scholar
• Vibhagool A, Sungkanuparph S, Mootsikapun P et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin. Infect. Dis.36, 1329–1331 (2003).
   PubMed Web of Science ®Google Scholar
• Mussini C, Pezzotti P, Miró JM et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin. Infect. Dis.38, 565–571 (2004).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Sobel J, Saag M et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis.30, 47–54 (2000).
   PubMed Web of Science ®Google Scholar
• Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. Surg. Neurol.63, 529–531 (2005).
   PubMedGoogle Scholar
• Newton PN, Thai le H, Tip NQ et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin. Infect. Dis.35, 769–772 (2002).
   PubMed Web of Science ®Google Scholar
• Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin. Infect. Dis.18, 789–792 (1994).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.Antimicrob. Agents Chemother.45, 2862–2864 (2001).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.Antimicrob. Agents Chemother.40, 1910–1913 (1996).
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Negroni R, Graybill JR et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother.56, 745–755 (2005).
   PubMed Web of Science ®Google Scholar
• van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of voriconazole on Cryptococcus neoformans.Antimicrob. Agents Chemother.48, 2014–2020 (2004).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis.36, 1122–1131 (2003).
   PubMed Web of Science ®Google Scholar
• Morrison VA. Echinocandin antifungals: review and update. Expert Rev. Anti Infect. Ther.4, 325–342 (2006).
   PubMedGoogle Scholar
• Pappas PG, Bustamante B, Ticona E et al. Recombinant interferon-γ 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis.189, 2185–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Robinson PA, Bauer M, Leal MA et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin. Infect. Dis.28, 82–92 (1999).
   PubMed Web of Science ®Google Scholar
• Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother.36, 690–692 (1992).
   PubMed Web of Science ®Google Scholar
• Coker RJ. Cryptococcal infection in AIDS. Int. J. STD AIDS3, 168–172 (1992).
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Apisarnthanarak A, Kiratisin P, Mundy LM, Bailey TC. Evaluation of Cryptococcus laurentii meningitis in a patient with HIV infection: a case report and review of the literature. Hawaii Med. J.65, 260–263 (2006).
   PubMedGoogle Scholar
• Dannaoui E, Abdul M, Arpin M et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob. Agents Chemother.50, 2464–2470 (2006).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cox GM. Drug resistance in Cryptococcus neoformans.Drug Resist. Updat.2, 259–269 (1999).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol.43, 2163–2167 (2005).
   PubMed Web of Science ®Google Scholar
• Bii CC, Makimura K, Abe S et al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses50, 25–30 (2007).
   PubMed Web of Science ®Google Scholar
• Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin. Infect. Dis.27, 260–264 (1998).
   PubMed Web of Science ®Google Scholar
• Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J. Antimicrob. Chemother.52, 683–686 (2003).
   PubMed Web of Science ®Google Scholar
• Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J. Antimicrob. Chemother.54, 563–565 (2004).
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Lau YJ, Chuang YC et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother.49, 512–517 (2005).
   PubMed Web of Science ®Google Scholar
• Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.J. Antimicrob. Chemother.56, 1144–1147 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA et al.In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother.50, 2009–2015 (2006).
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother.50, 917–921 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al.In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis.48, 201–205 (2004).
   PubMed Web of Science ®Google Scholar
• Shelburne SA, Darcourt J, White AC et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis.40, 1049–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F; French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS19, 1043–1049 (2005).
   PubMed Web of Science ®Google Scholar
• Shelburne SA, Hamill RJ, Rodriguez-Barradas MC et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore)81, 213–227 (2002).
   PubMed Web of Science ®Google Scholar
• Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J. Infect.51, e289–e297 (2005).
   PubMedGoogle Scholar
• Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin. Infect. Dis.35, e128–e133 (2002).
   PubMed Web of Science ®Google Scholar
• Blanche P, Gombert B, Ginsburg C et al. HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand. J. Infect. Dis.30, 615–616 (1998).
   PubMed Web of Science ®Google Scholar
• Masur H, Kaplan JE, Holmes KK; US Public Health Service; Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons – 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann. Intern. Med.137, 435–478 (2002).
   PubMed Web of Science ®Google Scholar
• Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst. Rev.3, CD004773 (2005).
   Google Scholar
• Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med.5, 140–143 (2004).
   PubMed Web of Science ®Google Scholar
• Larsen RA, Pappas PG, Perfect J et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother.49, 952–958 (2005).
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. Feasibility and prospects for a vaccine to prevent cryptococcosis. Med. Mycol.43, 667–680 (2005).
   PubMed Web of Science ®Google Scholar
• Coker RJ, Viviani M, Gazzard BG et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS7, 829–835 (1993).
   PubMed Web of Science ®Google Scholar
• Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med.326, 83–89 (1992).
   PubMed Web of Science ®Google Scholar
• Physician Desk Reference. Product listings. In: RED BOOK: Pharmacy’s Fundamental Reference. Thomson PDR, NJ, USA 211–245, 416, 480 (2006).
   Google Scholar
• Physician Desk Reference. Product information: antifungals. In: PDR Concise Prescribing Guide. Thomson PDR, NJ, USA 53–55 (2007).
   Google Scholar
• Havlir DV, Dubé MP, McCutchan JA et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin. Infect. Dis.27, 1369–1375 (1998).
   PubMed Web of Science ®Google Scholar
• Powderly WG, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N. Engl. J. Med.332, 700–705 (1995).
   PubMed Web of Science ®Google Scholar
• Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin. Infect. Dis.34, 277–284 (2002).
   PubMed Web of Science ®Google Scholar
• McKinsey DS, Wheat LJ, Cloud GA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis.28, 1049–1056 (1999).
   PubMed Web of Science ®Google Scholar